Choose Your Country or Region

Afuresertib (GSK2110183)

Name: Afuresertib (GSK2110183)
Brand: Selleck Chemicals
SKU: S7521
Rating: 5 (20 reviews)

Catalog No.S7521

For research use only.

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with K_i of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

Afuresertib (GSK2110183) Chemical Structure

CAS No. 1047644-62-1

Selleck's Afuresertib (GSK2110183) has been cited by 20 publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Related Compound Libraries

Other Akt Products

AT13148^New

AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
SC79^New

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
TIC10 (ONC201)^New

TIC10 (ONC201) inactivates Akt and ERK to induce TNF-related apoptosis-inducing ligand (TRAIL) through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.
Capivasertib (AZD5363)

Capivasertib (AZD5363) potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.
Ipatasertib (GDC-0068)

Ipatasertib (GDC-0068, RG7440) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.
GSK690693

GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. GSK690693 also potently inhibits AMPK and DAPK3 from the CAMK family with IC50 of 50 nM and 81 nM, respectively. GSK690693 affects Unc-51-like autophagy activating kinase 1 (ULK1) activity, robustly inhibits STING-dependent IRF3 activation. Phase 1.
Perifosine (KRX-0401)

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Triciribine (NSC 154020)

Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
Honokiol (NSC 293100)

Honokiol (NSC 293100) is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Honokiol causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. Honokiol inhibits hepatitis C virus (HCV) infection. Phase 3.

Download Inhibitor Catalog

Akt Signaling Pathway Map

Biological Activity

Description

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with K_i of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

Targets

Akt1 ^[1] (Cell-free assay)	Akt2 ^[1] (Cell-free assay)	Akt3 ^[1] (Cell-free assay)
0.08 nM(Ki)	2 nM(Ki)	2.6 nM(Ki)

In vitro

Afuresertib inhibits the kinase activity of the E17K AKT1 mutant protein with EC50 of 0.2 nM. Afuresertib shows a concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3b, PRAS40, FOXO and Caspase 9. Overall 65% of the hematological cell lines are sensitive to afuresertib (EC50 < 1 μM). Among tested solid tumor cell lines, 21% have EC50 < 1 μM in response to afuresertib.^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Sf9	MmG2SpVv[3Srb36gZZN{[Xl?	NUDVc\|B5PDBibXnudy=>	NHjWZYJKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJIh2dWGwIFHLWFEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5ic4Xid5Rz[XSnIIDoc5NxcG:{eXzheIlwdiC3c3nu[{BjcW:2aX6tZYh5NUGUS2LFVmF[W0[JSFjBMYFucWSnIIP1ZpN1emG2ZTDhcoQhY2ejbX3hMVM{WF2DVGCgbY5kfWKjdHXkJIZweiB2MDDtbY5{KGK7IITvdEBkd3WwdDDtbYNzd3CuYYTlJJNkcW62aXzsZZRqd25iY3;1cpRqdmdibXX0bI9lNCCLQ{WwJF0hOC5yMEGg{txONg>?	NWThXYd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
Sf9	NIf5TpJHfW6ldHnvckBie3OjeR?=	NVvaeohmPDBibXnudy=>	MlG3TY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDoeY1idiCDS2SzJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHO3YoP0doF1\SCyaH;zdIhwenmuYYTpc44hfXOrbnegZolwfGmwLXHofE1CWkuURWLBXXNHT0iKQT3hcYll\SC\|dXLzeJJifGViYX7kJHto[W2vYT2zN3BeSVSSIHnuZ5Vj[XSnZDDmc5IhPDBibXnud{BjgSC2b4CgZ492dnRibXnjdo9xdGG2ZTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oKG2ndHjv[EwhUUN3MDC9JFAvODBzNUi1JO69VS5?	MkPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
COLO205	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NYHHNZRyPzJiaILz	MWfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDU2xQOjB3IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{AtKEmFNUCgQUAxNjByOTFOwG0v	NHO0T5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
Sf9	MonWSpVv[3Srb36gZZN{[Xl?	NHzW[nc1OCCvaX7z	NV[2dnNSUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBpfW2jbjDBT3QzKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIIP1ZpN1emG2ZTDwbI9{eGixconsZZRqd25idYPpcoch[mmxdHnuMYFpgC2DUlvSSXJCYVOIR1jIRU1idWmmZTDzeYJ{fHKjdHWgZY5lKFupYX3tZU0{O1CfQWTQJIlv[3WkYYTl[EBnd3JiNECgcYlveyCkeTD0c5Ah[2:3boSgcYlkem:ybHH0[UB{[2mwdHnscIF1cW:wIHPveY51cW6pIH3leIhw\CxiSVO1NEA:KDBwMEGg{txONg>?	NFu0ZWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
MV522	Mk\tS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MnvOO\|IhcHK\|	MnjPS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUXY2OjJiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW\|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4xOTJizszNMi=>	MlXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
HT-29	M1Pq[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{CwdVczKGi{cx?=	Mmq5S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTHQuOjliY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW\|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4xOTVizszNMi=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H727	NFKxWoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NIfmbZo4OiCqcoO=	MVrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDd{NzDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf\|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1\|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjBzOTFOwG0v	MoTPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
SW1417	NULZZ25uT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MnH6O\|IhcHK\|	NUHpTo1MT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzNEG3JINmdGy\|IHH0JFE7OTBibX;sZZIhemG2aX:gc4Yh[2:vcH;1coQhcW5icILld4Vv[2Vib3[gUk18Oy2dMz3jfYNtd3C{b4D5cE02NSh{LX\seY9zdy12LXnv[I8ueGinbonsZY1qdm9rLU[sPE1lcW2ndHj5cE0hOix2LEeteJJqd3ixLUOsOEw3NDdvdHX0doFpgWS{bz2yTE1xgXKrZH;bOEw{NWSfcInybY1q\GmwLUGtfYxeeGinbonsgYFk\XSjbXnk[UBqdmO3YnH0[YQh\m:{IEeyJIhzeyxiSVO1NEA:KDBwMEOg{txONg>?	M2jmdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
Calu6	MnnSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYi3NkBpenN?	MlTFS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gR4FtfTZiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW\|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4xOzFizszNMi=>	MmjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
LS1034	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{DqWFczKGi{cx?=	MlzsS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUHMyODN2IHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvODRizszNMi=>	M2\Xd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
SW1463	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MYm3NkBpenN?	NGXHe21Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUXzF2NkOgZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt\|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC5yNEGg{txONg>?	NWnSN2NORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
RKO	M1jN[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MnXaO\|IhcHK\|	Mor2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVmtQKGOnbHzzJIF1KDF8MUCgcY9t[XJicnH0bY8hd2ZiY3;tdI92dmRiaX6gdJJme2WwY3Wgc4YhVi29Mz3bN{1kgWOub4Dyc5B6dC13LTiyMYZtfW:{bz20MYlw\G9vcHjlcplt[W2rbn:pMVYtQC2maX3leIh6dC1iMjy0MFcufHKrb4jvMVMtPCx4LEeteIV1emGqeXTyc{0zUC2yeYLp[I9cPCx\|LXTddJlzcW2rZHnuMVEugWyfcHjlcplthWGlZYThcYll\SCrbnP1ZoF1\WRiZn;yJFczKGi{czygTWM2OCB;IECuNFU1KM7:TT6=	MnfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
NCI-H508	M1OzUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWm3NkBpenN?	NUD5Tmg{T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NFgh[2WubIOgZZQhOTpzMDDtc4xieiC{YYTpc{Bw\iClb33wc5Vv\CCrbjDwdoV{\W6lZTDv[kBPNXt\|LWuzMYN6[2yxcILvdJltNTVvKEKt[ox2d3KxLUStbY9ldy2yaHXufYxidWmwbzmtOkw5NWSrbXX0bJltNSB{LESsO{11emmxeH:tN{w1NDZuNz30[ZRz[Wi7ZILvMVJJNXC7cnnkc3s1NDNvZG3wfZJqdWmmaX6tNU16dF2yaHXufYx:[WOndHHtbYRmKGmwY4XiZZRm\CCob4KgO\|IhcHK\|LDDJR\|UxKD1iMD6wPEDPxE1w	M2XoUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
NCI-H1155	NYHoUnRyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mne5O\|IhcHK\|	NVS3bHZLT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNVU2KGOnbHzzJIF1KDF8MUCgcY9t[XJicnH0bY8hd2ZiY3;tdI92dmRiaX6gdJJme2WwY3Wgc4YhVi29Mz3bN{1kgWOub4Dyc5B6dC13LTiyMYZtfW:{bz20MYlw\G9vcHjlcplt[W2rbn:pMVYtQC2maX3leIh6dC1iMjy0MFcufHKrb4jvMVMtPCx4LEeteIV1emGqeXTyc{0zUC2yeYLp[I9cPCx\|LXTddJlzcW2rZHnuMVEugWyfcHjlcplthWGlZYThcYll\SCrbnP1ZoF1\WRiZn;yJFczKGi{LDDJR\|UxKD1iMD6xNFEh\|ryPLh?=	MnTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
A427	NVfLcYV6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYW3NkBpenN?	M1HDNmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW\|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4yODNizszNMi=>	MljBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
KM12	Mo\4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MX23NkBpenN?	Ml:wS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT20yOiClZXzsd{BifCBzOkGwJI1wdGG{IILheIlwKG:oIHPvcZBwfW6mIHnuJJBz\XOnbnPlJI9nKE5ve{OtX\|Mu[3mlbH;wdo9xgWxvNT2oNk1ndHWxcn:tOE1qd2SxLYDo[Y56dGGvaX7vLU03NDhvZHnt[ZRpgWxvIEKsOEw4NXS{aX;4c{0{NDRuNjy3MZRmfHKjaInkdo8uOkhvcInybYRwYzRuMz3kYZB6emmvaXTpck0yNXmuXYDo[Y56dH2jY3X0ZY1q\GViaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCwMlExPCEQvF2u	NUi2W\|Z4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
HCT8	NELQXG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MnLVO\|IhcHK\|	M4HFPGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDhiY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW\|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4yPDNizszNMi=>	Mk\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
MDA-MB-175-VII	Mk\qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MlXZO\|IhcHK\|	M4j5cmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xO\|UuXkmLIHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvOTV3IN88UU4>	M13ESlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
A549	NX\JPVZFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXHFSnVFPzJiaILz	M1PrTmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW\|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4yPjRizszNMi=>	M3LndFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
NCI-H23	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M4q1d\|czKGi{cx?=	M1fXSWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkOgZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt\|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KCxiSVO1NEA:KDBwMUm5JO69VS5?	M2G2N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
SW837	NWfLS5VTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVn3WphDPzJiaILz	NX\PbZVuT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hW1d6M{egZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt\|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC5{NEig{txONg>?	NGLMSVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
SW480	M2f0c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{D3blczKGi{cx?=	M3nv[2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNYPDhyIHPlcIx{KGG2IEG6NVAhdW:uYYKgdoF1cW9ib3[gZ49ueG:3bnSgbY4heHKnc3XuZ4Uhd2ZiTj37N{1cOy2leXPsc5Bzd3C7bD21MUgzNW[udX;yc{01NWmxZH:tdIhmdnmuYX3pco8qNTZuOD3kbY1mfGi7bD2gNkw1NDdvdILpc5hwNTNuNDy2MFcufGW2cnHofYRzdy1{SD3wfZJq\G:dNDyzMYReeHm{aX3p[IlvNTFveXzddIhmdnmufXHj[ZRidWmmZTDpcoN2[mG2ZXSg[o9zKDd{IHjyd{whUUN3MDC9JFAvOjV7IN88UU4>	NF\qU2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
NCI-H1355	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHTkWI04OiCqcoO=	NFv3fFVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEGzOVUh[2WubIOgZZQhOTpzMDDtc4xieiC{YYTpc{Bw\iClb33wc5Vv\CCrbjDwdoV{\W6lZTDv[kBPNXt\|LWuzMYN6[2yxcILvdJltNTVvKEKt[ox2d3KxLUStbY9ldy2yaHXufYxidWmwbzmtOkw5NWSrbXX0bJltNSB{LESsO{11emmxeH:tN{w1NDZuNz30[ZRz[Wi7ZILvMVJJNXC7cnnkc3s1NDNvZG3wfZJqdWmmaX6tNU16dF2yaHXufYx:[WOndHHtbYRmKGmwY4XiZZRm\CCob4KgO\|IhcHJuIFnDOVAhRSByLkK2PEDPxE1w	M1TlXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
EFM19	NIrhUFJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NE\RTYc4OiCqcoO=	MlrjS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSWZOOTliY3XscJMh[XRiMUqxNEBud2yjcjDyZZRqdyCxZjDjc41xd3WwZDDpckBxemW\|ZX7j[UBw\iCQLYuzMXs{NWO7Y3zvdJJweHmuLUWtLFIu\my3b4LvMVQucW:mbz3wbIVvgWyjbXnuc{kuPix6LXTpcYV1cHmuLTCyMFQtPy22cnnvfI8uOyx2LE[sO{11\XS{YXj5[JJwNTKKLYD5dolld1t2LEOt[H1xgXKrbXnkbY4uOS27bG3wbIVvgWy;YXPleIFucWSnIHnuZ5Vj[XSnZDDmc5IhPzJiaILzMEBKSzVyIE2gNE4{KM7:TT6=	M33YXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
T84	NF\oRmNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MV[3NkBpenN?	MmnlS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWFg1KGOnbHzzJIF1KDF8MUCgcY9t[XJicnH0bY8hd2ZiY3;tdI92dmRiaX6gdJJme2WwY3Wgc4YhVi29Mz3bN{1kgWOub4Dyc5B6dC13LTiyMYZtfW:{bz20MYlw\G9vcHjlcplt[W2rbn:pMVYtQC2maX3leIh6dC1iMjy0MFcufHKrb4jvMVMtPCx4LEeteIV1emGqeXTyc{0zUC2yeYLp[I9cPCx\|LXTddJlzcW2rZHnuMVEugWyfcHjlcplthWGlZYThcYll\SCrbnP1ZoF1\WRiZn;yJFczKGi{czygTWM2OCB;IECuN\|A1KM7:TT6=	NWTIb\|hsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
COR-L23	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1v6dlczKGi{cx?=	NHH6cnJIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEKzJINmdGy\|IHH0JFE7OTBibX;sZZIhemG2aX:gc4Yh[2:vcH;1coQhcW5icILld4Vv[2Vib3[gUk18Oy2dMz3jfYNtd3C{b4D5cE02NSh{LX\seY9zdy12LXnv[I8ueGinbonsZY1qdm9rLU[sPE1lcW2ndHj5cE0hOix2LEeteJJqd3ixLUOsOEw3NDdvdHX0doFpgWS{bz2yTE1xgXKrZH;bOEw{NWSfcInybY1q\GmwLUGtfYxeeGinbonsgYFk\XSjbXnk[UBqdmO3YnH0[YQh\m:{IEeyJIhzeyBuIFnDOVAhRSByLkO2PEDPxE1w	M3O4W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
NCI-H1792	M{[2WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYnQXGJSPzJiaILz	M4HY[Wdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe5NkBk\WyuczDheEAyQjFyIH3vcIFzKHKjdHnvJI9nKGOxbYDveY5lKGmwIIDy[ZNmdmOnIH;mJG4ugzNvW{OtZ5lkdG:ycn;wfYwuPS1qMj3mcJVwem9vND3pc4RwNXCqZX75cIFucW6xKT22MFgu\GmvZYTofYwuKDJuNDy3MZRzcW:6bz2zMFQtPix5LYTleJJicHmmcn:tNmgueHm{aXTvX\|QtOy2mXYD5dolucWSrbj2xMZltZXCqZX75cJ1i[2W2YX3p[IUhcW6ldXLheIVlKG[xcjC3NkBpeixiSVO1NEA:KDBwM{e0JO69VS5?	NGLTZ\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
SW1573	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEPnRXo4OiCqcoO=	M3TQR2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNYOTV5MzDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf\|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1\|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjN6MjFOwG0v	MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
Calu3	NILLUWhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MW[3NkBpenN?	MYfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDZYx2OyClZXzsd{BifCBzOkGwJI1wdGG{IILheIlwKG:oIHPvcZBwfW6mIHnuJJBz\XOnbnPlJI9nKE5ve{OtX\|Mu[3mlbH;wdo9xgWxvNT2oNk1ndHWxcn:tOE1qd2SxLYDo[Y56dGGvaX7vLU03NDhvZHnt[ZRpgWxvIEKsOEw4NXS{aX;4c{0{NDRuNjy3MZRmfHKjaInkdo8uOkhvcInybYRwYzRuMz3kYZB6emmvaXTpck0yNXmuXYDo[Y56dH2jY3X0ZY1q\GViaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCwMlM6OiEQvF2u	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
HCC827	NILJ[mlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Mn[zO\|IhcHK\|	M4DETWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhESzh{NzDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf\|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1\|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjRyMTFOwG0v	MkniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
EFM19	NGLRWYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MkHaO\|IhcHK\|	M1XENGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGVHVTF7IHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO\|YYmsJGlEPTBiPTCwMlQ{KM7:TT6=	NFfuWm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
HOP62	MlLXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MUK3NkBpenN?	NX3tcosxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUE:SNkKgZ4VtdHNiYYSgNVoyOCCvb3zhdkBz[XSrbzDv[kBkd22yb4Xu[EBqdiCycnXz[Y5k\SCxZjDOMZs{NVt\|LXP5Z4xweHKxcInsMVUuMDJvZnz1c5JwNTRvaX;kc{1xcGWweXzhcYlvdylvNjy4MYRqdWW2aInsMUAzNDRuNz30dolwgG9vMzy0MFYtPy22ZYTyZYh6\HKxLULIMZB6emmmb2u0MFMu\F2yeYLpcYllcW5vMT35cH1xcGWweXz9ZYNmfGGvaXTlJIlv[3WkYYTl[EBnd3JiN{KgbJJ{NCCLQ{WwJF0hOC52OUig{txONg>?	MkSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
NCI-H508	Mo\1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXq3NkBpenN?	M3;obGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUC4JINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUAxNjV{MjFOwG0v	M{ezeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
SW900	MoPMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MkT1O\|IhcHK\|	NFP2S\|JIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUXzlyMDDj[YxteyCjdDCxPlExKG2xbHHyJJJifGmxIH;mJINwdXCxdX7kJIlvKHC{ZYPlcoNmKG:oIF6tf\|MuYzNvY4njcI9xem:yeXytOU0pOi2obIXvdo8uPC2rb3TvMZBp\W67bHHtbY5wMS14LEit[Ilu\XSqeXytJFItPCx5LYTybY95dy1\|LESsOkw4NXSndILhbJllem9vMlitdJlzcWSxW{SsN{1lZXC7cnntbYRqdi1zLYnsYZBp\W67bI3hZ4V1[W2rZHWgbY5kfWKjdHXkJIZweiB5MjDodpMtKEmFNUCgQUAxNjdzOTFOwG0v	NXS3VlhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
MDA-MB-175-VII	MnPIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NUHv[41oPzJiaILz	M2DqbWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xO\|UuXkmLIHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO\|YYmsJGlEPTBiPTCwMlc6PCEQvF2u	NEXRNYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
NCI-H1155	NX75V4FFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M4\IdFczKGi{cx?=	M{\1emdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUG1OUBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCFZXzsMZRqfGW{LVfsc{Bz\WGpZX70JIJie2WmIHHzd4F6NCCLQ{WwJF0hOC56NkWg{txONg>?	M1vR[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOTl2MkKvK\|5EcEWPQly8M4E,
DLD1	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXS3NkBpenN?	MkG2S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSGxFOSClZXzsd{BifCBzOkGwJI1wdGG{IILheIlwKG:oIHPvcZBwfW6mIHnuJJBz\XOnbnPlJI9nKE5ve{OtX\|Mu[3mlbH;wdo9xgWxvNT2oNk1ndHWxcn:tOE1qd2SxLYDo[Y56dGGvaX7vLU03NDhvZHnt[ZRpgWxvIEKsOEw4NXS{aX;4c{0{NDRuNjy3MZRmfHKjaInkdo8uOkhvcInybYRwYzRuMz3kYZB6emmvaXTpck0yNXmuXYDo[Y56dH2jY3X0ZY1q\GViaX7jeYJifGWmIH\vdkA4OiCqcoOsJGlEPTBiPTCwMlk{OiEQvF2u	NGPlUFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
HT-29	MkPnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MU[3NkBpenN?	NUXBUGZ3T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMkmgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS2WubD30bZRmei2JbH:gdoVi\2WwdDDiZZNm\CCjc4PhfUwhUUN3MDC9JFEvOzh\|IN88UU4>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
HCT8	M2\kc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MljDO\|IhcHK\|	NEnGflRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJS1R6IHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO\|YYmsJGlEPTBiPTCxMlU1OSEQvF2u	NITMVpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?
RKO	MorQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWS3NkBpenN?	NUK2T2RIT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO\|YYmsJGlEPTBiPTCxMlgxPiEQvF2u	MoXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
Calu6	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHL1Sno4OiCqcoO=	NIiyUVBIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBE[Wy3NjDj[YxteyCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBE\WyuLYTpeIVzNUeubzDy[YFo\W62IHLhd4VlKGG\|c3H5MEBKSzVyIE2gNk4yPTRizszNMi=>	NU\rS5RnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
KM12	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFPKUpQ4OiCqcoO=	MoXDS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gT20yOiClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDD[YxtNXSrdHXyMWdtdyC{ZXHn[Y51KGKjc3XkJIF{e2G7LDDJR\|UxKD1iMj6yOFch\|ryPLh?=	NYS2XXJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
COLO205	NULUU4VHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NGnXWXM4OiCqcoO=	NXrWSHhzT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OT{KwOUBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCFZXzsMZRqfGW{LVfsc{Bz\WGpZX70JIJie2WmIHHzd4F6NCCLQ{WwJF0hOi53Nkeg{txONg>?	NXXMZm9YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
MV522	M17KWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MWO3NkBpenN?	MUPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNWlUzOiClZXzsd{BqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDD[YxtNXSrdHXyMWdtdyC{ZXHn[Y51KGKjc3XkJIF{e2G7LDDJR\|UxKD1iMz6wOFQh\|ryPLh?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
LS1034	NFfzW\|dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MoL3O\|IhcHK\|	NVnhV5ZVT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVFNzMEO0JINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUA1NjN\|OTFOwG0v	NULNeFhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
NCI-H727	NG[2b\|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXK3NkBpenN?	MoT1S5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUh5MkegZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS2WubD30bZRmei2JbH:gdoVi\2WwdDDiZZNm\CCjc4PhfUwhUUN3MDC9JFQvPzl7IN88UU4>	MlvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
COR-L23	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M13Pd\|czKGi{cx?=	NWrZOY5OT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyyN{Bk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCFZXzsMZRqfGW{LVfsc{Bz\WGpZX70JIJie2WmIHHzd4F6NCCLQ{WwJF0hPS5\|N{Og{txONg>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
A549	MojvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MoDWO\|IhcHK\|	NITRdFlIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO\|YYmsJGlEPTBiPTC1Mlk6OyEQvF2u	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H1355	M3r6WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MnfqO\|IhcHK\|	MYfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDF\|NUWgZ4VtdHNiaX7jeYJifGWmIH\vdkA4OiCqcoOgZpkhS2WubD30bZRmei2JbH:gdoVi\2WwdDDiZZNm\CCjc4PhfUwhUUN3MDC9JFYvPjh3IN88UU4>	NUToRXlMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJzOUSyNk8oRkOqRV3CUFww[T5?
NCI-H23	Mn3qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NGTvNWI4OiCqcoO=	NEWzOWpIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKzJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUA4NjF{NDFOwG0v	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlE6PDJ{Lze+R4hGVUKOPD;hQi=>
NCI-H1792	NIPETphIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MYS3NkBpenN?	MkPqS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKNUhzN{myJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KEOnbHyteIl1\XJvR3zvJJJm[WenboSgZoF{\WRiYYPzZZktKEmFNUCgQUA4NjNyNzFOwG0v	MnT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIyQTR{Mj:nQmNpTU2ETEyvZV4>
SW1463	MnjNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVq3NkBpenN?	Ml7YS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV3cyPDZ\|IHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JGNmdGxvdHn0[ZIuT2yxIILlZYdmdnRiYnHz[YQh[XO\|YYmsJGlEPTBiPTC5MlczPSEQvF2u	NGj0[HE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjF7NEKyM{c,S2iHTVLMQE9iRg>?

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot

p-GSK3 / GSK3 / p-PRAS40 / PRAS40 / p-FOXO / p-Casp9 / p-AKT / AKT / p-MEK / p-ERK / Erk ; ATG3 / ATG12 / LC3B

24978597 30867818

In vivo

Mice bearing BT474 breast tumor xenografts are dosed with afuresertib (p.o.) at 10, 30 or 100 mg/kg daily which results in 8, 37 and 61% TGI, respectively. Mice bearing SKOV3 ovarian tumor xenografts are treated with 10, 30 and 100 mg/kg afuresertib which results in 23, 37 and 97% TGI, respectively.^[1]

Protocol (from reference)

Kinase Assay:^[1]	*Potency (Ki) of afuresertib:** The true potency (Ki*) of the inhibitor is initially determined at low enzyme concentrations (0.1 nM AKT1, 0.7 nM AKT2, and 0.2 nM AKT3) using a filter binding assay and then confirmed with progress curve analysis. In the filter binding assay, a pre-mix of enzyme plus inhibitor is incubated for 1 h and then added to a GSKα peptide (Ac-KKGGRARTSS-FAEPG-amide) and [γ³³P] ATP. Reactions are terminated after 2 h and the radio labeled AKT peptide product is captured in a phospho-cellulose filter plate. Progress curve analysis utilizes continuous real-time fluorescence detection of product formation using the Sox-AKT-tide substrate (Ac-ARKRERAYSF-d-Pro-Sox-Gly-NH2).
Cell Research:^[1]	Cell lines: Hematological cell lines and solid tumor cell lines Concentrations: 30 μM Incubation Time: 72 h Method: A 3-day proliferation assay using CellTiter-Glo is performed to measure the growth inhibition by the compounds at 0-30 μM. Cell growth is determined relative to untreated (DMSO) controls. EC50’s are calculated from inhibition curves using a 4- or 6-parameter fitting algorithm in the Assay Client application.
Animal Research:^[1]	Animal Models: Female athymic nude and SCID mice bearing SKOV3 or BT474 tumors Dosages: 100 mg/kg Administration: p.o.

References

[1] Dumble M, et al. PLoS One, 2014, 9(6):e100880.

Solubility (25°C)

In vitro	DMSO	85 mg/mL (198.91 mM)
	Ethanol	85 mg/mL (198.91 mM)
	Water	Insoluble

Chemical Information

Molecular Weight	427.32
Formula	C₁₈H₁₇Cl₂FN₄OS
CAS No.	1047644-62-1
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CN1C(=C(C=N1)Cl)C2=C(SC(=C2)C(=O)NC(CC3=CC(=CC=C3)F)CN)Cl

Download Afuresertib (GSK2110183) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04374630	Recruiting	Drug: Paclitaxel\|Drug: Afuresertib	Platinum-resistant Ovarian Cancer	Laekna Limited	June 9 2020	Phase 2
NCT04060394	Recruiting	Drug: Phase I and Phase II: LAE001/prednisone + afuresertib	Metastatic Castration-resistant Prostate Cancer	Laekna Limited	September 13 2019	Phase 1\|Phase 2
NCT02235740	Terminated	Drug: Afuresertib\|Drug: Carfilzomib	Cancer	Novartis\|Amgen	November 2014	Phase 1
NCT02240212	Completed	Drug: Afuresertib\|Drug: Paclitaxel	Cancer	Novartis Pharmaceuticals\|Novartis	October 2014	Phase 1
NCT02177682	Terminated	Drug: Afuresertib	Neoplasms Haematologic	Novartis Pharmaceuticals\|Novartis	August 13 2014	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):